The stock is down more than 50% from its 52-week high.Earlier this year, share prices of Iovance Biotherapeutics (IOVA -1.23%) were soaring after one of its therapies obtained approval from regulators. Iovance stock would go on to reach share price highs of more than $18. Today, however, the stock trades at less than half that price. And in just three months, it has fallen by more than 40% as the hype surrounding the business appears to have evaporated.Is it too late to invest in Iovance, or could the best ...